Structure Therapeutics is trading 8.2% down at $50.64 in pre-market, pulling back after a multi-month rally fueled by positive obesity-pill data and acquisition rumors.
- The stock is undergoing a sentiment reset and profit-taking following a significant price surge linked to Phase 2 obesity trial success.
- Recent volatility has been driven by mixed analyst price-target revisions and takeover speculation, with today's move occurring in the absence of new company-specific headlines.